Galenica (GALE) Corporate Presentation summary

Sales performance and growth drivers

• Net sales increased by 4.7% to CHF 3,922 million in 2024, with both H1 and H2 contributing to growth.

• Sales growth was supported by both Products & Care (+3.9%) and Logistics & IT (+5.3%) segments.

• Retail (B2C) sales rose 4.1%, while Professionals (B2B) grew 4.7%.

• Wholesale sales increased by 5.1%, driven by market share gains in physicians and pharmacies.

• Logistics & IT Services saw a 9.2% rise, mainly from internal IT services and pre-wholesale distribution.

Segment and market highlights

• Local Pharmacies expanded by 10 locations, contributing a 1.7% expansion impact.

• Generics substitution rate increased from 75.2% to 79.2% by end of 2024.

• Products & Brands sales grew 3.5%, with international sales up 16.2% and Swiss market sales stable.

• Services for Professionals posted 7.5% growth, led by homecare and nursing home services.

• Pharmacies at Home sales declined by 2.1%.

Swiss pharmaceutical and consumer health market context

• Swiss pharmaceutical market grew 3.5% to CHF 7,688 million, with local pharmacies up 3.5% and physicians up 5.7%.

• Hospital sales rose 2.4%, while mail-order pharmacies and drugstores saw declines.

• Consumer healthcare market increased 1.1% to CHF 2,803.2 million, with OTC up 2.2%.

• Non-medication segment and personal care saw slight declines.

• Strong H2 growth in the pharmaceutical market was supported by two additional sales days.